PARP-inhibitors applied to BRCA1-null PDX models (ID 474174) - BioProject

Format

Choose Destination

Accession: PRJEB26804 ID: 474174

PARP-inhibitors applied to BRCA1-null PDX models

BRCA1 deficiencies cause breast, ovarian and other cancers, and render tumours hypersensitive to PARP-inhibitors. More...

Accession	PRJEB26804
Scope	Monoisolate
Submission	Registration date: 1-Jun-2018 CAMBRIDGE INSTITUTE - CANCER RESEARCH UK AND UNIVERSITY OF CAMBRIDGE

Project Data:

Parameter	Value
Data volume, Gbases	108
Data volume, Mbytes	40963

Supplemental Content

Targeting JNK Pathway Expands Human Hematopoietic Stem Cells
Targeting JNK Pathway Expands Human Hematopoietic Stem Cells
Targeting JNK Pathway Expands Human Hematopoietic Stem Cells

BioProject
Wickerhamiella versatilis strain:t-1
Wickerhamiella versatilis strain:t-1
Wickerhamiella versatilis strain:t-1 Genome sequencing and assembly

BioProject
salt lake metagenome
salt lake metagenome
Tuosu Salt lake Raw sequence reads

BioProject
PARP-inhibitors applied to BRCA1-null PDX models
PARP-inhibitors applied to BRCA1-null PDX models
Expression changes in BRCA1-deficient breast cancer PDX models treated with PARP-inhibitors.

BioProject
Homo sapiens
Homo sapiens
Regulatory T cell modulation by CBP/EP300 bromodomain inhibition [RNA-seq]

BioProject

Your browsing activity is empty.

Activity recording is turned off.